公开(公告)号：WO2012083164A1

公开(公告)日：2012-06-21

申请号：PCT/US2011/065486

申请日：2011-12-16

Applicant: ABBOTT LABORATORIES ,  DEGOEY, David A. ,  KRUEGER, Allan C. ,  HUTCHINS, Charles W. ,  KATI, Warren M. ,  CARROLL, William A.

Inventor： DEGOEY, David A. ,  KRUEGER, Allan C. ,  HUTCHINS, Charles W. ,  KATI, Warren M. ,  CARROLL, William A.

IPC: C07D403/12 ,  C07D403/14 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/4184

CPC classification number: A61K31/55 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/506 ,  A61K38/00 ,  A61K45/06 ,  C07D205/04 ,  C07D207/16 ,  C07D207/22 ,  C07D209/52 ,  C07D211/60 ,  C07D263/06 ,  C07D277/06 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04 ,  C07K5/06034 ,  C07K5/06043 ,  C07K5/0606 ,  C07K5/06069 ,  C07K5/06078 ,  C07K5/06139

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Abstract translation: 描述了有效抑制丙型肝炎病毒（“HCV”）复制的化合物。 本发明还涉及制备这种化合物的方法，包含这些化合物的组合物，以及使用这些化合物治疗HCV感染的方法。

公开(公告)号：WO2012051361A1

公开(公告)日：2012-04-19

申请号：PCT/US2011/056045

申请日：2011-10-12

Applicant: ABBOTT LABORATORIES ,  DEGOEY, David A. ,  KATI, Warren M. ,  HUTCHINS, Charles W. ,  DONNER, Pamela L. ,  KRUEGER, Allan C. ,  RANDOLPH, John T. ,  MOTTER, Christopher E. ,  NELSON, Lissa T. ,  PATEL, Sachel V. ,  MATULENKO, Mark A. ,  KEDDY, Ryan G. ,  JINKERSON, Tammie K. ,  GAO, Yi ,  LIU, Dachun ,  PRATT, John K. ,  ROCKWAY, Todd W. ,  MARING, Clarence J. ,  HUTCHINSON, Douglas K. ,  FLENTGE, Charles A. ,  WAGNER, Rolf ,  TUFANO, Michael D. ,  BETEBENNER, David A. ,  SARRIS, Kathy ,  WOLLER, Kevin R. ,  WAGAW, Sebel H. ,  CALIFANO, Jean C. ,  LI, Wenke ,  CASPI, Daniel D. ,  BELLIZZI, Mary E. ,  CARROLL, William A.

Inventor： DEGOEY, David A. ,  KATI, Warren M. ,  HUTCHINS, Charles W. ,  DONNER, Pamela L. ,  KRUEGER, Allan C. ,  RANDOLPH, John T. ,  MOTTER, Christopher E. ,  NELSON, Lissa T. ,  PATEL, Sachel V. ,  MATULENKO, Mark A. ,  KEDDY, Ryan G. ,  JINKERSON, Tammie K. ,  GAO, Yi ,  LIU, Dachun ,  PRATT, John K. ,  ROCKWAY, Todd W. ,  MARING, Clarence J. ,  HUTCHINSON, Douglas K. ,  FLENTGE, Charles A. ,  WAGNER, Rolf ,  TUFANO, Michael D. ,  BETEBENNER, David A. ,  SARRIS, Kathy ,  WOLLER, Kevin R. ,  WAGAW, Sebel H. ,  CALIFANO, Jean C. ,  LI, Wenke ,  CASPI, Daniel D. ,  BELLIZZI, Mary E. ,  CARROLL, William A.

IPC: C07D403/14

CPC classification number: A61K31/454 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/435 ,  A61K31/4355 ,  A61K31/438 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/695 ,  A61K45/06 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/00 ,  C07D491/113 ,  C07F7/02 ,  Y02P20/582

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (HCV) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Abstract translation: 描述了有效抑制丙型肝炎病毒（HCV）复制的化合物。 本发明还涉及制备这种化合物的方法，包含这些化合物的组合物，以及使用这些化合物治疗HCV感染的方法。

公开(公告)号：WO2010111437A1

公开(公告)日：2010-09-30

申请号：PCT/US2010/028561

申请日：2010-03-25

Applicant: ABBOTT LABORATORIES ,  ROCKWAY, Todd W. ,  BETEBENNER, David A. ,  DEGOEY, David A. ,  FLENTGE, Charles A. ,  HUTCHINSON, Douglas K. ,  KATI, Warren M. ,  KRUEGER, Allan C. ,  LIU, Dachun ,  LONGENECKER, Kenton L. ,  PRATT, John K. ,  STEWART, Kent D. ,  WAGNER, Rolf

Inventor： ROCKWAY, Todd W. ,  BETEBENNER, David A. ,  DEGOEY, David A. ,  FLENTGE, Charles A. ,  HUTCHINSON, Douglas K. ,  KATI, Warren M. ,  KRUEGER, Allan C. ,  LIU, Dachun ,  LONGENECKER, Kenton L. ,  PRATT, John K. ,  STEWART, Kent D. ,  WAGNER, Rolf

IPC: C07D401/04 ,  C07D403/04 ,  C07D407/04 ,  C07D409/14 ,  A61K31/513 ,  A61P31/12

CPC classification number: C07D401/04 ,  C07D403/04 ,  C07D407/04 ,  C07D409/14

Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

Abstract translation: 本发明涉及：（a）特别是抑制HCV的化合物及其盐; （b）可用于制备这些化合物和盐的中间体; （c）包含这些化合物和盐的组合物; （d）制备此类中间体，化合物，盐和组合物的方法; （e）使用这些化合物，盐和组合物的方法; 和（f）包含这些化合物，盐和组合物的试剂盒。

公开(公告)号：WO2009039127A1

公开(公告)日：2009-03-26

申请号：PCT/US2008/076576

申请日：2008-09-17

Applicant: ABBOTT LABORATORIES ,  WAGNER, Rolf ,  TUFANO, Michael D. ,  STEWART, Kent D. ,  ROCKWAY, Todd W. ,  RANDOLPH, John T. ,  PRATT, John K. ,  MOTTER, Christopher E. ,  MARING, Clarence J. ,  LONGENECKER, Kenton L. ,  LIU, Yaya ,  LIU, Dachun ,  KRUEGER, Allan C. ,  KATI, Warren M. ,  HUTCHINSON, Douglas K. ,  HUANG, Peggy P. ,  FLENTGE, Charles A. ,  DONNER, Pamela L. ,  DEGOEY, David A. ,  BETEBENNER, David A. ,  BARNES, David M. ,  CHEN, Shuang ,  FRANCZYK II, Thaddeus S. ,  GAO, Yi ,  HAIGHT, Anthony R. ,  HENGEVELD, John E. ,  HENRY, Rodger F. ,  KOTECKI, Brian J. ,  LOU, Xiaochun ,  SARRIS, Kathy ,  ZHANG, Geoff G. Z.

Inventor： WAGNER, Rolf ,  TUFANO, Michael D. ,  STEWART, Kent D. ,  ROCKWAY, Todd W. ,  RANDOLPH, John T. ,  PRATT, John K. ,  MOTTER, Christopher E. ,  MARING, Clarence J. ,  LONGENECKER, Kenton L. ,  LIU, Yaya ,  LIU, Dachun ,  KRUEGER, Allan C. ,  KATI, Warren M. ,  HUTCHINSON, Douglas K. ,  HUANG, Peggy P. ,  FLENTGE, Charles A. ,  DONNER, Pamela L. ,  DEGOEY, David A. ,  BETEBENNER, David A. ,  BARNES, David M. ,  CHEN, Shuang ,  FRANCZYK II, Thaddeus S. ,  GAO, Yi ,  HAIGHT, Anthony R. ,  HENGEVELD, John E. ,  HENRY, Rodger F. ,  KOTECKI, Brian J. ,  LOU, Xiaochun ,  SARRIS, Kathy ,  ZHANG, Geoff G. Z.

IPC: C07D239/22 ,  C07D239/54 ,  C07D401/10 ,  C07D403/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10 ,  A61P31/12 ,  A61K31/513

CPC classification number: A61K31/513 ,  A61K31/5377 ,  C07D239/22 ,  C07D239/54 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10 ,  C07D417/14

Abstract: Present application relates to the compounds of formula I useful to treat hepatitis C (HCV) infections. In the structure of the disclosed compounds is the uracil or thymine derivative linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two-atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2>4-dioxo-3,4-dihydropyrimidin-1 (2H)- y!)2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E)-N-(4(3-t- butyl-5-(2,4-dioxo-3)4-dihydropyrimidin-1 (2H)-yl)2-methoxy-styryl- phenyl)methanesulfonamide.

Abstract translation: 本申请涉及可用于治疗丙型肝炎（HCV）感染的式I化合物。 所公开的化合物的结构是通过亚苯基连接成稠合的2-环环系（R6）或者另外通过另外的两个原子连接基（L）与5-6元单环（R6）连接的尿嘧啶或胸腺嘧啶衍生物。 应用进一步公开了两种特定化合物的多晶型物和假多晶型物：N-（6（3-叔丁基-5-（2,4-二氧代-3,4-二氢嘧啶-1（2H） - 基）-2-甲氧基 - 苯基 ）萘-2-基）甲磺酰胺和（E）-N-（4（3-叔丁基-5-（2,4-二氧代-3）4-二氢嘧啶-1（2H） - 基）2-甲氧基 - 苯乙烯基 - 苯基）甲磺酰胺。

公开(公告)号：WO2010144646A3

公开(公告)日：2010-12-16

申请号：PCT/US2010/038077

申请日：2010-06-10

Applicant: ABBOTT LABORATORIES ,  DEGOEY, David A. ,  KATI, Warren M. ,  HUTCHINS, Charles W. ,  DONNER, Pamela L. ,  KRUEGER, Allan C. ,  RANDOLPH, John T. ,  MOTTER, Christopher E. ,  NELSON, Lissa T. ,  PATEL, Sachin V. ,  MATULENKO, Mark A. ,  KEDDY, Ryan G. ,  JINKERSON, Tammie K. ,  SOLTWEDEL, Todd N. ,  HUTCHINSON, Douglas K. ,  FLENTGE, Charles A. ,  WAGNER, Rolf ,  MARING, Clarence J. ,  TUFANO, Michael D. ,  BETEBENNER, David A. ,  ROCKWAY, Todd W. ,  LIU, Dachun ,  PRATT, John K. ,  LAVIN, Michael J. ,  SARRIS, Kathy ,  WOLLER, Kevin R. ,  WAGAW, Seble H. ,  CALIFANO, Jean C. ,  LI, Wenke ,  CASPI, Daniel, D. ,  BELLIZZI, Mary, E.

Inventor： DEGOEY, David A. ,  KATI, Warren M. ,  HUTCHINS, Charles W. ,  DONNER, Pamela L. ,  KRUEGER, Allan C. ,  RANDOLPH, John T. ,  MOTTER, Christopher E. ,  NELSON, Lissa T. ,  PATEL, Sachin V. ,  MATULENKO, Mark A. ,  KEDDY, Ryan G. ,  JINKERSON, Tammie K. ,  SOLTWEDEL, Todd N. ,  HUTCHINSON, Douglas K. ,  FLENTGE, Charles A. ,  WAGNER, Rolf ,  MARING, Clarence J. ,  TUFANO, Michael D. ,  BETEBENNER, David A. ,  ROCKWAY, Todd W. ,  LIU, Dachun ,  PRATT, John K. ,  LAVIN, Michael J. ,  SARRIS, Kathy ,  WOLLER, Kevin R. ,  WAGAW, Seble H. ,  CALIFANO, Jean C. ,  LI, Wenke ,  CASPI, Daniel, D. ,  BELLIZZI, Mary, E.

IPC: C07D403/14 ,  C07D401/14 ,  C07D417/14 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4196 ,  A61K31/4439 ,  A61P31/14

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

公开(公告)号：EP2421845A1

公开(公告)日：2012-02-29

申请号：EP10712220.2

申请日：2010-03-25

Applicant: Abbott Laboratories

Inventor： ROCKWAY, Todd W. ,  BETEBENNER, David A. ,  DEGOEY, David A. ,  FLENTGE, Charles A. ,  HUTCHINSON, Douglas K. ,  KATI, Warren M. ,  KRUEGER, Allan C. ,  LIU, Dachun ,  LONGENECKER, Kenton L. ,  PRATT, John K. ,  STEWART, Kent D. ,  WAGNER, Rolf ,  MARING, Clarence, J.

IPC: C07D401/04 ,  C07D403/04 ,  C07D407/04 ,  C07D409/14 ,  A61K31/513 ,  A61P31/12

CPC classification number: C07D401/04 ,  C07D403/04 ,  C07D407/04 ,  C07D409/14

Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

公开(公告)号：EP1358154A2

公开(公告)日：2003-11-05

申请号：EP00972042.6

申请日：2000-10-10

Applicant: Abbott Laboratories

Inventor： MARING, Clarence J. ,  GIRANDA, Vincent L. ,  KEMPF, Dale J. ,  STOLL, Vincent S. ,  SUN, Minghua ,  ZHAO, Chen ,  GU, Yu Gui ,  HANESSIAN, Stephen ,  WANG, Gary T. ,  KRUEGER, Allan C. ,  CHEN, Hui-Ju ,  CHEN, Yuanwei ,  DEGOEY, David A. ,  FLOSI, William J. ,  GRAMPOVNIK, David J. ,  KATI, Warren M. ,  KENNEDY, April L. ,  KLEIN, Larry L. ,  LIN, Zhen ,  MADIGAN, Darold L. ,  MCDANIEL, Keith F. ,  MUCHMORE, Steven W. ,  SHAM, Hing L. ,  STEWART, Kent D. ,  TU, Noah P. ,  WAGENAAR, Frank L. ,  WANG, Sheldon ,  WIEDEMAN, Paul E. ,  XU, Yibo ,  YEUNG, Ming C. ,  BAYRAKDARIAN, Malken ,  LUO, Xuehong

IPC: C07D207/16 ,  C07D403/04 ,  C07D417/04

CPC classification number: C07D207/16 ,  C07D207/26 ,  C07D207/327 ,  C07D207/38 ,  C07D207/46 ,  C07D231/12 ,  C07D233/56 ,  C07D249/08 ,  C07D303/16 ,  C07D403/04 ,  C07D405/04 ,  C07D405/06 ,  C07D409/06 ,  C07D413/04 ,  C07D417/04 ,  C07D417/06

Abstract: Enantiomerically enriched compounds having the absolute stereochemistry of the formula (I) or a pharmaceutically acceptable salt, ester or prodrug thereof, which are useful for inhibiting neuraminidases from disease-causing microorganisms, especially, influenza neuraminidase. Also disclosed are compositions and methods for preventing and treating diseases caused by microorganisms having a neuraminidase, processes for preparing the compounds and synthetic intermediates used in these processes.

公开(公告)号：EP2421845B1

公开(公告)日：2013-04-17

申请号：EP10712220.2

申请日：2010-03-25

Applicant: Abbott Laboratories

Inventor： ROCKWAY, Todd W. ,  BETEBENNER, David A. ,  DEGOEY, David A. ,  FLENTGE, Charles A. ,  HUTCHINSON, Douglas K. ,  KATI, Warren M. ,  KRUEGER, Allan C. ,  LIU, Dachun ,  LONGENECKER, Kenton L. ,  PRATT, John K. ,  STEWART, Kent D. ,  WAGNER, Rolf ,  MARING, Clarence, J.

IPC: C07D401/04 ,  C07D403/04 ,  C07D407/04 ,  C07D409/14 ,  A61K31/513 ,  A61P31/12

CPC classification number: C07D401/04 ,  C07D403/04 ,  C07D407/04 ,  C07D409/14

公开(公告)号：EP2337781A2

公开(公告)日：2011-06-29

申请号：EP10724656.3

申请日：2010-06-10

Applicant: Abbott Laboratories

Inventor： RANDOLPH, John T. ,  DEGOEY, David A. ,  KATI, Warren M. ,  HUTCHINS, Charles W. ,  DONNER, Pamela L. ,  KRUEGER, Allan C. ,  MOTTER, Christopher E. ,  NELSON, Lissa T. ,  PATEL, Sachin V. ,  MATULENKO, Mark A. ,  KEDDY, Ryan G. ,  JINKERSON, Tammie K. ,  SOLTWEDEL, Todd N. ,  HUTCHINSON, Douglas K. ,  FLENTGE, Charles A. ,  WAGNER, Rolf ,  MARING, Clarence J. ,  TUFANO, Michael D. ,  BETEBENNER, David A. ,  ROCKWAY, Todd W. ,  LIU, Dachun ,  PRATT, John K. ,  LAVIN, Michael J. ,  SARRIS, Kathy ,  WOLLER, Kevin R. ,  WAGAW, Seble H. ,  CALIFANO, Jean C. ,  LI, Wenke ,  CASPI, Daniel.D. ,  BELLIZZI, Mary, E.

IPC: C07D403/14 ,  C07D401/14 ,  C07D417/14 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4196 ,  A61K31/4439 ,  A61P31/14

CPC classification number: C07F9/65583 ,  C07C33/26 ,  C07C201/06 ,  C07C205/19 ,  C07D207/08 ,  C07D207/09 ,  C07D207/16 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D453/00 ,  C07D471/04 ,  C07D491/113 ,  C07K5/06

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

公开(公告)号：EP2222646A1

公开(公告)日：2010-09-01

申请号：EP08831873.8

申请日：2008-09-17

Applicant: Abbott Laboratories

Inventor： WAGNER, Rolf ,  TUFANO, Michael D. ,  STEWART, Kent D. ,  ROCKWAY, Todd W. ,  RANDOLPH, John T. ,  PRATT, John K. ,  MOTTER, Christopher E. ,  MARING, Clarence J. ,  LONGENECKER, Kenton L. ,  LIU, Yaya ,  LIU, Dachun ,  KRUEGER, Allan C. ,  KATI, Warren M. ,  HUTCHINSON, Douglas K. ,  HUANG, Peggy P. ,  FLENTGE, Charles A. ,  DONNER,Pamela L. ,  DEGOEY, David A. ,  BETEBENNER, David A. ,  BARNES, David M. ,  CHEN, Shuang ,  FRANCZYK II, Thaddeus S. ,  GAO, Yi ,  HAIGHT, Anthony R. ,  HENGEVELD, John E. ,  HENRY, Rodger F. ,  KOTECKI, Brian J. ,  LOU, Xiaochun ,  SARRIS, Kathy ,  ZHANG, Geoff G. Z.

IPC: C07D239/22 ,  C07D239/54 ,  C07D401/10 ,  C07D403/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10 ,  A61P31/12 ,  A61K31/513

CPC classification number: A61K31/513 ,  A61K31/5377 ,  C07D239/22 ,  C07D239/54 ,  C07D401/10 ,  C07D403/10 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10 ,  C07D417/14

Abstract: Present application relates to the compounds of formula I useful to treat hepatitis C (HCV) infections. In the structure of the disclosed compounds is the uracil or thymine derivative linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two-atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2>4-dioxo-3,4-dihydropyrimidin-1 (2H)- y!)2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E)-N-(4(3-t- butyl-5-(2,4-dioxo-3)4-dihydropyrimidin-1 (2H)-yl)2-methoxy-styryl- phenyl)methanesulfonamide.